Key result
Single RAAS blockade with aliskiren or irbesartan reduced the urine/plasma renin ratio approximately 4-fold, and dual blockade reduced it more than 10-fold in patients with type 2 diabetes.
Why the study?
Do aliskiren, irbesartan, or their combination alter urinary angiotensinogen and renin levels in patients with type 2 diabetes, hypertension, and albuminuria?
RCT (n=22)
Random order
Do aliskiren, irbesartan, or their combination alter urinary angiotensinogen and renin levels in patients with type 2 diabetes, hypertension, and albuminuria?
Urinary angiotensinogen is a marker of filtration barrier damage, whereas the urine/plasma renin ratio may reflect the renal efficacy of RAAS blockade.
Answers are grounded in this paper and cite their sources.
Urinary RAAS markers reflect local blockade effects; challenges their utility as circulating-independent renal indicators in diabetic albuminuria.
OBJECTIVE: Urinary levels of renin-angiotensin-aldosterone system (RAAS) components may reflect renal RAAS activity and/or the renal efficacy of RAAS inhibition. Our aim was to determine whether urinary angiotensinogen and renin are circulating RAAS-independent markers during RAAS blockade. METHODS: Urinary and plasma levels of angiotensinogen, renin, and albumin were measured in 22 patients with type 2 diabetes, hypertension, and albuminuria, during 2-month treatment periods with placebo, aliskiren, irbesartan, or their combination in random order in a crossover study. RESULTS: Aliskiren and irbesartan both increased plasma renin 3-4-fold, and above 10-fold when combined. Irbesartan decreased plasma angiotensinogen by approximately 25%, and no changes in plasma angiotensinogen were observed during the combination. Urine contained aliskiren at micromolar levels, blocking urinary renin by above 90%. Both blockers reduced urinary angiotensinogen, significant for irbesartan only. Combination blockade reduced urinary angiotensinogen even further. Reductions in urinary angiotensinogen paralleled albuminuria changes, and the urine/plasma concentration ratio of angiotensinogen was identical to that of albumin under all conditions. In contrast, urinary renin did not follow albumin, and remained unaltered after all treatments. Yet, the urine/plasma concentration ratio of renin was more than 100-fold higher than that of angiotensinogen and albumin, and approximately 4-fold reduced by single RAAS blockade, and more than 10-fold by dual RAAS blockade. CONCLUSIONS: Aliskiren filters into urine and influences urinary renin measurements. The urine/plasma renin ratio, but not urinary renin alone, may reflect the renal efficacy of RAAS blockade. Urinary angiotensinogen is a marker of filtration barrier damage rather than intrarenal RAAS activity.
No takes yet. Share an insight, caveat, or question.
Persson et al. (2013) conducted an RCT in Type 2 diabetes, hypertension, and albuminuria (n=22). Aliskiren, irbesartan, or their combination vs. Placebo was evaluated on Urinary and plasma levels of angiotensinogen, renin, and albumin. Single RAAS blockade with aliskiren or irbesartan reduced the urine/plasma renin ratio approximately 4-fold, and dual blockade reduced it more than 10-fold in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: